The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects
M. Fitzgerald, S. Snape, S. Febbraro, D. Singh, C. Patwell, B. Ruparelia, N. Snell (Slough, Merthyr Tydfil, Manchester, United Kingdom)
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Session: New clinical trials of asthma and COPD drugs
Session type: Poster Discussion
Number: 3401
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Fitzgerald, S. Snape, S. Febbraro, D. Singh, C. Patwell, B. Ruparelia, N. Snell (Slough, Merthyr Tydfil, Manchester, United Kingdom). The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects. Eur Respir J 2013; 42: Suppl. 57, 3401
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Safety, PK and PD of ARRY-502, a CRTh2 antagonist, in healthy subjects with a history of seasonal allergies Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Safety profile and pharmacokinetics of an inhaled GATA-3-specific DNAzyme in a phase Ib study in patients with stable allergic asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects Source: Annual Congress 2013 –Treatment of asthma Year: 2013
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014
The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Pharmacological treatment of asthma today Source: Eur Respir J 2001; 18: 34S-40S Year: 2001
Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
A double blind randomised placebo controlled trial of the PPAR-gamma agonist pioglitazone in mild asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020